Current Report Filing (8-k)
November 03 2022 - 8:42AM
Edgar (US Regulatory)
0001504167
false
0001504167
2022-11-03
2022-11-03
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 3, 2022
TIMBER
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
001-37411 |
|
59-3843182 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
110
Allen Road, Suite 401
Basking
Ridge, NJ 07920
(Address
of principal executive offices)
Registrant’s
telephone number, including area code: (908) 636-7160
N/A
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock, $0.001 Par Value |
|
TMBR |
|
The
NYSE American, LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On
November 3, 2022, Timber Pharmaceuticals, Inc. (the “Company”) announced that trading of its shares of common stock
has been halted by New York Stock Exchange (“NYSE” or the “Exchange”) due to its low trading price on November
1, 2022. The Company expects the trading halt to remain in effect until after the Company’s special meeting of stockholders scheduled
for November 7, 2022, at 1:00 P.M. (EST) (the “Special Meeting”), at which the Company is seeking stockholder approval to
complete a reverse stock split in order to regain compliance with NYSE’s listing requirements, and consummation of such reverse
stock split based on the parameters being voted on at the Special Meeting. Subject to NYSE approval, it is anticipated that trading will
resume on the NYSE American following the implementation of the reverse stock split. Although not anticipated by the Company,
the Exchange could maintain the trading halt. The Exchange could also suspend trading and move to delist the Company’s common
stock if the price per share post-split does not meet the requirements of Section 1003(f)(v) of the NYSE American Company Guide.
| Item
9.01 |
Financial
Statements and Exhibits. |
(d)
Exhibits.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
Timber
Pharmaceuticals, Inc. |
| |
|
| Date:
November 3, 2022 |
By: |
/s/
John Koconis |
| |
Name: |
John
Koconis |
| |
Title: |
Chief
Executive Officer and Chairman of the Board of Directors |
Timber Pharmaceuticals (AMEX:TMBR)
Historical Stock Chart
From Nov 2024 to Dec 2024
Timber Pharmaceuticals (AMEX:TMBR)
Historical Stock Chart
From Dec 2023 to Dec 2024
